At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 38 enrolled

Drug / intervention

Meloxicam +1 moredrug

Likely dose

Meloxicam 15 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02078102

NCT02078102Phase 2Completed

Compare CT.gov

A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

Sherif S. Farag·interventional·Posted Mar 5, 2014·Updated Feb 21, 2021

In Brief

A Phase 2 clinical trial evaluating Meloxicam and Filgrastim for Multiple Myeloma and Non-Hodgkin's Lymphoma. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The trial is an open label Simon optimal two-stage Phase II trial of fixed doses of oral meloxicam and subcutaneous filgrastim to assess the safety and efficacy in mobilizing autologous peripheral blood stem cells (PBSC) from multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) patients planning to undergo high-dose chemotherapy with stem cell support. Clinical data regarding the cellular composition and function of the graft mobilized by this combination will be obtained.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMultiple Myeloma, Non-Hodgkin's Lymphoma

CountriesUnited States

CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished

2014201520162017201820192020202120222023202420252026

First PostedMar 2014

Enrollment StartMar 2014

Primary CompletionNov 2018

Study CompletionFeb 2019

TodayJul 2026

First PostedMar 5, 2014

Enrollment StartMar 11, 2014

Primary CompletionNov 6, 2018

Study CompletionFeb 21, 2019

TodayJul 2, 2026

Enrollment to primary: 4.7 yearsPosted 12.3 years ago

Interventions

Meloxicamdrug

15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.

Filgrastimdrug

Filgrastim will be subcutaneously injected in one or two sites at home.